Masafumi Fukagawa
Overview
Explore the profile of Masafumi Fukagawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
493
Citations
5995
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishimoto M, Hasegawa T, Murashima M, Noma H, Nishiwaki H, Yamada S, et al.
Clin J Am Soc Nephrol
. 2025 Mar;
PMID: 40085178
Background: It is necessary to update the evidence of each phosphate-lowering agent on dialysis patients. Methods: From the CENTRAL, MEDLINE, EMBASE, and ClinicalTrial.gov databases, randomized controlled trials (RCTs) using oral...
2.
Hamano N, Komaba H, Tanaka H, Takahashi H, Takahashi Y, Hyodo T, et al.
Am J Nephrol
. 2025 Feb;
:1-9.
PMID: 39978330
Introduction: Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO...
3.
Imaizumi T, Komaba H, Hamano T, Nangaku M, Murotani K, Hasegawa T, et al.
Clin Kidney J
. 2025 Feb;
18(2):sfae398.
PMID: 39950153
Background: The slope of estimated glomerular filtration rate (eGFR) is a promising surrogate endpoint in patients with chronic kidney disease (CKD). However, current evidence is mainly derived from Western populations...
4.
Akizawa T, Urano N, Ikejiri K, Nakanishi K, Fukagawa M
Ther Apher Dial
. 2025 Jan;
29(2):157-169.
PMID: 39829064
Patients on dialysis often develop hyperphosphatemia, contributing to an increased risk of cardiovascular events and mortality. Currently, several types of phosphate binders (PBs) exist for the treatment of hyperphosphatemia, but...
5.
Komaba H, Imaizumi T, Hamano T, Fujii N, Abe M, Hanafusa N, et al.
Kidney Int Rep
. 2024 Oct;
9(10):2956-2969.
PMID: 39430172
Introduction: Secondary hyperparathyroidism (SHPT) affects bone metabolism and may lead to bone fragility. However, there is conflicting evidence as to whether parathyroid hormone (PTH) levels are associated with fracture risk...
6.
Hamano T, Koiwa F, Isaka Y, Yokoyama K, Fukagawa M, Inagaki Y, et al.
Am J Nephrol
. 2024 Sep;
56(1):70-84.
PMID: 39299219
Introduction: Upacicalcet is a novel injectable calcimimetic. This phase 3 multicenter open-label study aimed to assess the long-term efficacy and safety of upacicalcet in hemodialysis (HD) patients with secondary hyperparathyroidism...
7.
Onozawa Y, Koizumi M, Nakagawa Y, Ogura G, Oki M, Wada T, et al.
CEN Case Rep
. 2024 Aug;
PMID: 39162947
Pauci-immune crescentic glomerulonephritis (PICGN) is one of the pathologies causing rapidly progressive glomerulonephritis, often associated with anti-neutrophil cytoplasmic antibody (ANCA); however, in 10-30% of cases, ANCAs are negative. While a...
8.
9.
Yamamoto S, Jorgensen H, Zhao J, Karaboyas A, Komaba H, Vervloet M, et al.
Kidney Int Rep
. 2024 May;
9(4):863-876.
PMID: 38765600
Introduction: Secondary hyperparathyroidism (SHPT) increases the risk of fractures and cardiovascular (CV) disease in patients on hemodialysis (HD). The relationship between parathyroid hormone (PTH) and outcomes has been inconsistent, possibly...
10.
Wakamatsu T, Yamamoto S, Matsuo K, Taniguchi M, Hamano T, Fukagawa M, et al.
J Bone Miner Metab
. 2024 Mar;
42(3):316-325.
PMID: 38536478
Introduction: This study aimed to assess the effectiveness of calcimimetics in reducing the risk of fractures in dialysis patients with secondary hyperparathyroidism (SHPT). Material And Methods: A comprehensive literature search...